Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AL 001 - Beijing Anlong Biopharmaceutical

Next Previous
Search
Drug Profile

AL 001 - Beijing Anlong Biopharmaceutical

Alternative Names: AL-001 - Beijing Anlong Biopharmaceutical

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Anlong Biopharmaceutical
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Wet age-related macular degeneration

Most Recent Events

  • 21 Feb 2025 Beijing Anlong Biopharmaceutical plans a phase-II trial for Wet age-related macular degeneration in China (Intraocular, Injection) (NCT06839339)
  • 11 Sep 2023 Phase-I/II clinical trials in Wet age-related macular degeneration (In adults, In the elderly) in China (Ophthalmic)
  • 30 Apr 2023 NMPA approves clinical trial application for AL 001 in Wet age-related macular degeneration (Beijing Anlong Biopharmaceutical website, December 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top